EQUASENS: Acquisition of the German company ADV and creation of
PHARMAGEST Germany
Villers-lès-Nancy, 23 November 2023 - 6:00 p.m.
(CET)
PRESS RELEASE
Acquisition of the German company
ADVand creation of PHARMAGEST Germany
EQUASENS, in partnership with
ARZ HAAN, a German market leader for services and software
solutions for healthcare providers, acquires ADV (Apotheken
Datenverarbeitung GmbH & Co. KG), which becomes
PHARMAGEST Germany, through a holding company 6%-held by ARZ HAAN
and 94%-held by EQUASENS.
-
PHARMAGEST Germany will invest in
developing technology and technical building blocks, as
well as a sales network to reinforce ADV's software
offering.
-
This acquisition marks a new milestone in the deployment of the
growth strategy of EQUASENS, already present in Germany in the
medication compliance segment through its subsidiary that markets
the MultiMeds pill dispenser and robot. EQUASENS is in this
way strengthening its position in the German market in its core
pharmacy business.
EQUASENS acquires
ADV.
EQUASENS, a leading healthcare software
publisher (Euronext Paris™ - Compartment A - ISIN: FR 0012882389 -
Ticker: EQS) today announces the acquisition of 100% of the capital
of AD Apotheken Datenverarbeitung GmbH & Co. KG (ADV) in
partnership with ARZ HAAN.
ADV, founded in 1986, specialises in IT and
software solutions for pharmacies. As an independent software
vendor, ADV is recognized in Germany for the quality and range of
its offering, its customer-focused culture and its ability to adapt
its solutions to changing market conditions.
ADV is the developer of the GAWIS business
software solution which is based on proven, high-performance
technologies offering a comprehensive range of modules and
services: dispensing assistance, invoicing, order processing,
business intelligence, etc. And in order to meet all needs of the
German market, GAWIS is connected to an entire ecosystem of
complementary solutions: self-service kiosks and digital shelves,
dispensing robots and checkout kiosks. As a result, this software
solution is perfectly adapted to the configuration of the German
market and also to developments in the German healthcare sector,
which, like other European markets, is currently engaged in a
digital transformation.
ADV is also the developer of Optipharm pharmacy
software, and OPTIPHARM PLUS GmbH, the publisher of this solution
is a wholly-owned subsidiary. ADV has already equipped nearly 400
of Germany's 17,500 pharmacies with its two software offerings,
GAWIS and Optipharm, despite the absence of a sales team. As of 1
December 2023, ADV thus becomes PHARMAGEST Germany.
ADV's Chief Operating Officer, Rupert SIERP,
commented: "With the German healthcare system on the verge of major
transformations, ADV is confronted with a number of complex
challenges. With EQUASENS as its parent company, ADV will benefit
from the support of a solid partner committed to promoting
efficiencies in the pharmacy sector. Our existing teams will
continue to support ADV and Optipharm users, just as they always
have, while benefiting from the active support of EQUASENS’
specialists. In collaboration with EQUASENS, ADV will in this way
continue to grow and develop innovative solutions for the German
pharmacy market.”
Creation of an EQUASENS Germany holding
company in partnership with ARZ HAAN
With nine operating subsidiaries and around
1,000 employees at more than ten locations, ARZ HAAN AG is a
leading provider of services to the German healthcare system.
Through these specialised subsidiaries, the Group develops and
markets innovative service solutions for the healthcare sector.
Through its broad range of offerings, from software solutions to
digital financing services, the Group supports healthcare
professionals in performing their day-to-day activities. More than
17,000 customers, including 4,000 pharmacies, from 30 different
professional groups put their trust in the performance and
innovative strength of this group of companies.
Philipp Siebelt, spokesman for the ARZ HAAN
Group, emphasised: "As an independent company with more than 50
years of service, supporting the core businesses of dispensing
pharmacies is the heart of our strategy. The EQUASENS Germany joint
venture will allow us to maintain our commitment to the long-term
future of Germany's pharmacies.”
A new milestone in the deployment of
EQUASENS' strategy in Germany,
The acquisition of ADV, the pharmacy software
solutions specialist in Germany, in partnership with ARZ HAAN, a
leading provider of services to healthcare professionals,
inaugurates Equasens expansion into the German pharmacy management
software market.
The contribution of its technologies, the
patient-centred approach of its European software solutions and the
Group's and business development capabilities will enable
PHARMAGEST Germany to become a significant player in this market
over the next few years. "Our goal is to become one of the top
three software publishers in Germany within the next 5 years by
introducing a disruptive solution in a market where digital
transformation is rapidly building momentum," concluded Denis
Supplisson, Chief Executive Officer of Equasens Group.
About Group Equasens
Founded more than 35 years ago, Equasens Group,
which now has more than 1,200 employees in Europe, is the leading
publisher of software solutions for the healthcare industry in
terms of the diversity of its business applications and market
share.
Equasens Group’s specialised business
applications facilitate the day-to-day work of healthcare
professionals and their teams, working in private practice,
collaborative medical structures or healthcare establishments. The
Group also provides comprehensive support to healthcare
professionals in the transformation of their profession by
developing electronic equipment, digital solutions and healthcare
robotics, as well as financing and training adapted to their
specific needs.
And reflecting the spirit of its tagline "more
technology for more humanity", the Group is a leading provider of
interoperability solutions that improve coordination between
healthcare professionals, their communications and data exchange
resulting in better patient care and a more efficient healthcare
system.
Listed on Euronext Paris™ - Compartment A
Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020
- CAC® SMALL and CAC® All-TradableIncluded in the Euronext Tech
Leaders segment and the European Rising Tech label
Eligible for the Deferred Settlement Service (“Service à
Réglement Différé” - SRD) and equity savings accounts invested in
small and mid caps (PEA-PME).ISIN: FR 0012882389 – Ticker Code:
EQS
Get all the news about the Equasens Group
www.equasens.com and on
LinkedIn
CONTACTS
Analyst and Investor
Relations: Chief Administrative and Financial Officer:
Frédérique SchmidtTel.: +33 (0)3 83 15 90 67 -
frederique.schmidt@equasens.com
Financial Press:
FIN’EXTENSO - Isabelle Aprile
Tel.: +33 (0)6
17 38 61 78 –
i.aprile@finextenso.fr
- EQUASENS_PRESSRELEASE_20231123_ADV_EN
Equasens (EU:EQS)
過去 株価チャート
から 10 2024 まで 11 2024
Equasens (EU:EQS)
過去 株価チャート
から 11 2023 まで 11 2024